MicroDose Technologies, Inc. (PRNewsFoto/MicroDose Technologies, Inc.)
MONMOUTH JUNCTION, N.J., Aug. 6 /PRNewswire/ — MicroDose Technologies, Inc., a privately held drug delivery and specialty pharmaceuticals company, today announces top line results from a glucose clamp study of the QDose inhaled insulin product. MicroDose, through its joint venture with Vectura Group plc, QDose Limited, has developed a highly efficient, rapid acting, insulin inhaler, based upon MicroDose’s proprietary electronic inhaler technology and Vectura’s dry powder insulin formulation.
Posts under ‘QDose’
MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Bristol-Myers Squibb And QDose Announce Collaboration To Develop Inhaled Insulin For The Treatment of Diabetes
NEW YORK, NEW YORK (September 10, 2003) — Bristol-Myers Squibb Company (NYSE: BMY) and QDose, a joint venture between MicroDose Technologies, Inc. and Quadrant Drug Delivery, Ltd., today announced that the companies have entered into a licensing agreement for the QDose inhaled insulin product.